Baheal Pharma (301015.SZ) was recently named on the "2024 China Emerging Pharmaceutical Innovators" list at the 41st National Pharmaceutical Industry Information Conference, hosted by the China National Pharmaceutical Industry Information Center. The conference, themed "Perseverance, Innovation, and Bright Future," focused on the latest industry policy dynamics, explored development trends, and promoted the deep integration of the pharmaceutical industry with the entire innovation ecosystem. During the event, several authoritative lists, including the "2023 Top 100 Chinese Pharmaceutical Companies," were unveiled, with Baheal Pharma honored for its initiatives and strategic layout in supporting pharmaceutical innovation.

The "China Emerging Pharmaceutical Innovators" list, established in 2020, is curated by the China National Pharmaceutical Industry Information Center in collaboration with the Chinese Academy of Medical Sciences and the Shanghai Institute of Pharmaceutical Industry. This expert panel conducts research and analysis based on objective data to identify the rising innovative enterprises within China's pharmaceutical sector. The evaluation criteria for this list are divided into two main categories: products and enterprises. On the product level, the assessment focuses on innovation, investment, technological advancements, and competitive environment. On the enterprise level, the criteria include characteristics, driving forces, strategic planning, and developmental progress.

As a platform dedicated to supporting innovation in the pharmaceutical industry, Baheal Pharma focuses its core business on the development, manufacturing, and commercialization of medical innovations. Through technological advancements, they aim to optimize medical scenarios. Leveraging its expertise in modern traditional Chinese medicine (TCM) and advanced controlled-release formulations, Baheal Pharma has established a robust R&D and production system for both Chinese and Western medicines. This has resulted in the development of several innovative products with independent intellectual property rights. The company continuously drives the technical development and production conversion of pioneering medical innovations. In addition, Baheal Pharma utilizes its mature, professional commercialization capabilities and its nationwide marketing network to accelerate the introduction of high-quality healthcare products into clinical applications. This strategic approach has successfully incubated multiple leading brands across various categories.

In recent years, the parent company, Baheal Pharma Group, has been actively advancing medical innovation by delving deep into the early stages of groundbreaking research in collaboration with national-level research institutions. They seek to cultivate and develop "first-in-class" potential and breakthrough technologies. Aligned with the Group's strategic focus on technological innovation, Baheal Pharma has successfully commercialized several cutting-edge products. These include CH Biomedical's fully magnetic levitation artificial heart, Medis's electromagnetic-guided ultrasound puncture devices, and WeHealth's home-use electrocardiographs.

Moreover, Baheal Pharma has secured commercialization rights for innovative products such as RADIO Pharma's first-in-class nuclear medicine tumor imaging diagnostic agent 99mTc-3PRGD2 and SPECT imaging devices, as well as RabPharma's pioneering peptide-drug conjugate (PDC) therapeutics. This strategic approach ensures that Baheal Pharma remains at the forefront of medical innovation and continues to bring advanced medical solutions to market.

Looking ahead, as the Group's early-stage innovations come to fruition, BAHEAL will leverage its industrial capabilities to drive the production and commercialization of cutting-edge pharmaceuticals and medical devices. This will accelerate the introduction of breakthrough medical products into clinical settings. BAHEAL remains committed to contributing to the flourishing development of medical innovation in China, driving progress in medical science and technology.